Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 12, 2021

LifeLines: Finding Light

Author(s)Melissa Bernstein

Melissa Bernstein, founder of toy company Melissa & Doug, talks about accepting the self in totality and journeying inwards.

Melissa Bernstein shares insights based on her own experiences from her book, LifeLines, with Psychiatric Times^TM.

Melissa Bernstein is the chief creative officer of Melissa & Doug and the founder of LifeLines.com.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

depressive disorder

Presenting Our September 2026 Theme: Depressive Disorders

September 1st 2026

psychiatry on trial

Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?

ByFernando Espí Forcén, MD, PhD,Susan Hatters Friedman, MD, MSt, DFAPA

August 27th 2026

Perimenopausal Depression May Signal a Hormonal Component: When to Consider HRT

ByNardin Valentin, DO

August 26th 2026

digital vs print

Digital Amnesia and Why Print Should Be Prized

ByRonald W. Pies, MD

August 21st 2026

TRD: Matching Patients to the Right Treatment

ByMichael E. Thase, MD

August 11th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness